Circular Genomics Inc.
@CircGenomics
Circular Genomics is the global leader in the use of circular RNA as a novel biomarker to power precision psychiatry.
We are excited to share that our CEO, Paul Sargeant, PhD, will be speaking at the Dubai Family Office Investment Summit on June 12, 2025. He’ll be sharing insights on how innovation in Circular RNA is shaping the future of precision medicine in mental health.
When it comes to selecting the right treatment for #MDD patients, pharmacogenomic tests (PGx) only tell part of the story — focusing on how the body metabolizes medications. MindLight uses circular RNA to assess a patient's likelihood of response to SSRIs. Learn more:…
Exciting news from our funded investigators @CircGenomics! Our investment is advancing circRNA, a novel blood-based biomarker for diagnosing and predicting Alzheimer's progression, supported by Diagnostics Accelerators (DxA).
Circular Genomics has been awarded a $250K investment from the Alzheimer’s Drug Discovery Foundation to advance our circular RNA blood-based early detection diagnostic testing for Alzheimer’s Disease. Read the full press release here: hubs.la/Q03wdq7H0
In this week's San Diego Newsletter: Adcentrx gets FDA Orphan Drug nod for gastric cancer drug; @CircGenomics snags $250K for Alzheimer’s RNA test; @iambic_ai + @Rev_Medicine launch partnership; @UCSDExtStudies offers Business of Biotech course. Subscribe: bit.ly/4iqn5b1
Circular Genomics has been awarded a $250K investment from the Alzheimer’s Drug Discovery Foundation to advance our circular RNA blood-based early detection diagnostic testing for Alzheimer’s Disease. Read the full press release here: hubs.la/Q03wdq7H0
🎙️ Hear Dr. Madhukar Trivedi, Professor of Psychiatry at UT Southwestern Medical School, discuss how the MindLight™ Antidepressant Response Test uses circular RNA to help clinicians make more informed treatment decisions — giving patients the best chance at relief, faster.…
Treating Major Depressive Disorder is complex, and the current standard often leaves patients waiting weeks to see if treatment works. For physicians, finding the right antidepressant can feel like educated guesswork. But with the MindLight™ Antidepressant Response Test,…
We are live at the American Association of Nurse Practitioner meeting! Stop by booth #237 to learn how MindLight can improve treatment planning for patients diagnosed with #MajorDepressiveDisorder. #AANP2025 #PrecisionPsychiatry #MentalHealth
We’re excited to exhibit at the AANP National Conference in San Diego from June 17–22, 2025! Looking forward to connecting with NPs and sharing how genomic innovation is advancing mental health care. Stop by booth 237 to learn more! #AANP2025 #PrecisionPsychiatry #MentalHealth
Justin T. Brown, PhD, our Senior Director of Business Development, will be attending the BIO International Convention June 16–19, 2025 at the Boston Convention & Exhibition Center. Meet with Justin to discuss partnering with us on circRNA-based Dx! #BIO2025
We’re thrilled to welcome our Commercial Advisory Board members: Melissa Reilly, JD, MBA; Andrew J. Lechleiter; Laura Viaches; and James Grana, PhD. Their deep expertise across healthcare strategy, growth, and innovation will be invaluable as we advance Circular Genomics’…
🧠 June is #Alzheimers & #BrainAwareness Month! Take charge of your brain health: ✔️ Move more ✔️ Sleep better ✔️ Eat smart ✔️ Stay mentally active ✔️ Know the signs At Circular Genomics, we're advancing brain health through circular RNA & precision medicine. #GoPurple #ENDALZ
June is Men’s Mental Health Awareness Month — a time to bring attention to the unique mental health challenges men face and to break down the stigma surrounding them. Too often, men are encouraged to stay silent about their struggles. But the truth is: Asking for help is not a…
For some patients with #MajorDepressiveDisorder, it can take up to 1 year to find the right treatment. MindLight™ uses circular RNA technology to help predict a patient’s likelihood of response to SSRIs. Learn more: hubs.la/Q03p01vT0
At Circular Genomics, we're pioneering a new era in mental health care. By identifying brain-enriched circRNA biomarkers in blood, we're enabling clinicians to predict patient responses to SSRI antidepressants—moving towards personalized, effective treatment planning.
That’s a wrap on #APAAM25! From presenting our research on circular RNA to highlighting the clinical value of the MindLight™ test, our team enjoyed engaging with dedicated healthcare providers who share our mission to advance mental health care.
We are live at the #APA2025 meeting! Visit Circular Genomics at Booth #2114 to learn how MindLight can support treatment planning for patients diagnosed with #MajorDepressive Disorder.
We’re excited to share that Greg Papageorgiou, PhD, our Lab Manager, will be presenting a poster at the American Psychiatric Association (APA) 2025 Annual Meeting. Stop by the poster and booth #2114 to learn more!
Today is National Mental Health Provider Appreciation Day 💙 We’re grateful for the dedicated professionals who support individuals living with mental illness. Your compassion, care, and impact matter—today and every day. #MentalHealthProviderAppreciation #ThankYouProviders…
May is #MentalHealthAwarenessMonth — a time to advocate for more personalized, science-driven care. At Circular Genomics, we’re advancing precision psychiatry for depression & Alzheimer’s by using brain-derived biomarkers to help guide treatment decisions. #MindLight…
